Barclays
PRME icon

Barclays’s Prime Medicine PRME Stock Holding History

Barclays’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$639K Buy
209,218
+121,160
+138% +$402K ﹤0.01% 3330
2026
Q2 		$325K Buy
88,058
+24,285
+38% +$80.7K ﹤0.01% 3450
2026
Q1 		$222K Sell
63,773
-300,053
-82% -$1.14M ﹤0.01% 3632
2025
Q4 		$1.26M Buy
363,826
+247,926
+214% +$1.1M ﹤0.01% 3276
2025
Q3 		$642K Buy
115,900
+1,098
+1% +$4.46K ﹤0.01% 3641
2025
Q2 		$284K Buy
114,802
+43,378
+61% +$66.9K ﹤0.01% 4075
2025
Q1 		$142K Sell
71,424
-26,197
-27% -$66.8K ﹤0.01% 4257
2024
Q4 		$285K Buy
97,621
+12,924
+15% +$45.4K ﹤0.01% 4140
2024
Q3 		$328K Buy
84,697
+65,593
+343% +$304K ﹤0.01% 4035
2024
Q2 		$98.2K Sell
19,104
-8,486
-31% -$51.4K ﹤0.01% 3917
2024
Q1 		$193K Sell
27,590
-26,645
-49% -$202K ﹤0.01% 4133
2023
Q4 		$481K Sell
54,235
-10,905
-17% -$84K ﹤0.01% 3901
2023
Q3 		$621K Buy
65,140
+57,261
+727% +$744K ﹤0.01% 2666
2023
Q2 		$115K Buy
7,879
+2,543
+48% +$35.5K ﹤0.01% 3504
2023
Q1 		$65.6K Buy
5,336
+2,549
+91% +$41.5K ﹤0.01% 4356
2022
Q4 		$51.8K Buy
+2,787
New +$50.3K ﹤0.01% 4539

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Alessandra Capital Management
Alessandra Capital Management Torrance, California $142M AUM 42.73% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Barclays's PRME Position: Q3 2026 in Review

Barclays increased its Prime Medicine (PRME) stake by 138% in Q3 2026, buying an estimated $402K and bringing the position to 209,218 shares worth $639K. The position accounts for ﹤0.01% of the portfolio, ranked #3330.

Barclays first reported a position in PRME in Q4 2022 and has held it in 16 quarters since. The position peaked at $1.26M in Q4 2025. 62 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • Barclays held 209,218 shares of Prime Medicine worth $639K as of Q3 2026.
  • Barclays bought 121,160 Prime Medicine shares in Q3 2026, an estimated $402K.
  • Prime Medicine made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3330 holding.
  • Barclays first reported a position in Prime Medicine in Q4 2022 and has held it in 16 quarters since.
  • Barclays's Prime Medicine position peaked at $1.26M in Q4 2025.
  • 62 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.